Related Experiment Video

Updated: May 8, 2026

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing (ChIP-seq)
09:52

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing (ChIP-seq)

Published on: April 19, 2013

TLR-2 gene polymorphisms and susceptibility to cancer: evidence from meta-analysis

Xiao-Qin Wang1, Li Liu, Yong Liu

  • 11 Department of Pediatric Cardiology, West-China Second University Hospital , Sichuan University, Cheng Du, People's Republic of China .

Genetic Testing and Molecular Biomarkers
|September 3, 2013
PubMed

Insights

Genetic variations in Toll-like receptor 2 (TLR-2) influence cancer susceptibility. A meta-analysis found the -196 to -174 del polymorphism is linked to increased cancer risk, while rs3804099 is associated with decreased risk.

Area of Science:

  • Immunogenetics
  • Cancer Epidemiology
  • Molecular Biology

Background:

  • Genetic polymorphisms in Toll-like receptor (TLR) genes can alter immune responses to TLR ligands, potentially influencing cancer susceptibility.
  • Previous epidemiological studies on the association between TLR gene polymorphisms and cancer risk have yielded inconsistent results.
  • Toll-like receptor 2 (TLR-2) plays a crucial role in innate immunity and has been implicated in various cancers.

Purpose of the Study:

  • To investigate the association between four specific polymorphisms in the TLR-2 gene (rs5743708, -196 to -174 del, rs3804099, and rs3804100) and cancer risk.
  • To conduct a comprehensive meta-analysis of available case-control studies to clarify the role of TLR-2 polymorphisms in cancer development.

Main Methods:

  • A meta-analysis was performed on 20 case-control studies published up to November 2012.
  • The analysis focused on four selected polymorphisms within the TLR-2 gene: rs5743708, -196 to -174 del, rs3804099, and rs3804100.
  • Summary odds ratios (OR) and 95% confidence intervals (CIs) were calculated for each polymorphism to assess cancer risk.

Main Results:

  • The -196 to -174 del polymorphism in TLR-2 was statistically associated with an elevated cancer risk across various genetic models (allele, dominant, recessive, codominant).
  • Specifically, the -196 to -174 del allele showed a significantly increased risk in 'other cancers' subgroup analysis.
  • Conversely, the rs3804099 polymorphism in TLR-2 was associated with a decreased cancer risk.

Conclusions:

  • Polymorphisms in the TLR-2 gene, particularly the -196 to -174 del allele, may play a role in cancer development, contributing to altered cancer susceptibility.
  • The findings suggest that genetic variations in TLR-2 can modulate an individual's risk of developing certain cancers.
  • Further research is warranted to elucidate the precise mechanisms by which TLR-2 polymorphisms influence cancer pathogenesis.

More Related Videos

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Related Concept Videos

Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...